At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Bortezomib for Multiple Myeloma. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy in research participants with relapsed high risk MM \[defined as gene expression profile (GEP) 70 gene score ≥0.66 and/or metaphase chromosomal abnormalities and/or high LDH ≥ 360U/L\] by establishing the (near) complete response rate. Response rate will be compared to case matched historical controls (patients who relapsed on Total Therapy 2 or 3 with high-risk MM defined as above). Disease-free survival and overall survival will be captured but are not primary or secondary endpoints.
Study Details
Timeline
Interventions
bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.